Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Observational Study
. 2015 Jan;20(1):72-6.
doi: 10.1634/theoncologist.2014-0308. Epub 2014 Nov 19.

Medically induced euthyroid hypothyroxinemia may extend survival in compassionate need cancer patients: an observational study

Aleck Hercbergs  1 , Rebecca E Johnson  2 , Osnat Ashur-Fabian  2 , David H Garfield  2 , Paul J Davis  2
Affiliations
Observational Study

Medically induced euthyroid hypothyroxinemia may extend survival in compassionate need cancer patients: an observational study

Aleck Hercbergs et al. Oncologist. 2015 Jan.

Abstract

Background: Clinical studies have shown that interventional lowering of serum free thyroxine (FT4) may be associated with extended survival in patients with some terminal cancers. The report of success with this approach in glioblastoma multiforme caused involvement of the author (A.H.) in the prospective consultative management of 23 end-stage solid tumor patients in whom hypothyroxinemia was induced to prolong life.

Patients and methods: Patients were self-referred or recommended by attending physicians to the author (A.H.) and had advanced cancers of the brain, ovary, lung, pancreas, salivary gland, and breast or had mesothelioma or soft-tissue sarcoma. Hypothyroxinemia was achieved in euthyroid patients by using methimazole, with the addition of 3,3',5-triiodo-L-thyronine (L-T3) to prevent hypothyroidism and suppress endogenous thyrotropin (TSH). In patients with pre-existent primary hypothyroidism, T3 administration was substituted for T4 replacement. Serum FT4 and TSH concentrations were serially monitored to enable adjustments to drug therapy and prevent clinical hypothyroidism. Survival was measured from the date of hypothyroxinemia induction with T3 or methimazole plus T3. Outcomes were compared with the odds of death based on the Surveillance Epidemiology and End Results and American Joint Committee on Cancer databases and literature reports.

Results: The survival time of 83% (19 of 23) of patients exceeded the 20% expected 1-year survival for this hypothyroxinemic, end-stage cancer group. The difference between actual and expected survival was significant.

Conclusion: Although this is an uncontrolled observational experience with frank limitations, compassionate medical induction of hypothyroxinemia should be considered for patients with advanced cancers to whom other avenues of treatment are closed.

Keywords: Cancer; Hypothyroxinemia; Survival; Triiodothyronine.

PubMed Disclaimer

Conflict of interest statement

Disclosures of potential conflicts of interest may be found at the end of this article.

References

    1. Cheng SY, Leonard JL, Davis PJ. Molecular aspects of thyroid hormone actions. Endocr Rev. 2010;31:139–170. - PMC - PubMed
    1. Hercbergs A. The thyroid gland as an intrinsic biologic response-modifier in advanced neoplasia—a novel paradigm. In Vivo. 1996;10:245–247. - PubMed
    1. Davis PJ, Davis FB, Mousa SA, et al. Membrane receptor for thyroid hormone: Physiologic and pharmacologic implications. Annu Rev Pharmacol Toxicol. 2011;51:99–115. - PubMed
    1. Moeller LC, Führer D. Thyroid hormone, thyroid hormone receptors, and cancer: A clinical perspective. Endocr Relat Cancer. 2013;20:R19–R29. - PubMed
    1. Hercbergs AA, Goyal LK, Suh JH, et al. Propylthiouracil-induced chemical hypothyroidism with high-dose tamoxifen prolongs survival in recurrent high grade glioma: A phase I/II study. Anticancer Res. 2003;23:617–626. - PubMed

Publication types

MeSH terms